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101Prediction of postdischarge venous
thromboembolism using a risk assessment model
James C. Iannuzzi, MD,a Kate C. Young, PhD,c Michael J. Kim, MD,a David L. Gillespie, MD,b
John R. T. Monson, MD,a and Fergal J. Fleming, MD,a Rochester, NY
Objective: The risk of postdischarge venous thromboembolism (VTE) (either deep vein or pulmonary embolism) is
increasingly recognized yet the prescription of postdischarge thromboprophylaxis is inconsistent. There is a paucity of
information to aid clinicians in identifying surgical patients who are at increased risk for postdischarge VTE. This study
aimed to determine the incidence and risk factors associated with symptomatic postdischarge VTE and develop a risk
score to identify patients who may beneﬁt from extended duration thromboprophylaxis.
Methods: This was a retrospective study. All nonorthopedic cases in which the patient was discharged alive without
inpatient VTE were selected from the 2005-2009 National Surgical Quality Improvement Program database. A multi-
variate logistic regression was used to create a risk score for postdischarge VTE prediction. The dataset was split into two-
thirds for risk score development and validated in the remaining one-third.
Results: The overall incidence of early postdischarge VTE for 2005-2009 National Surgical Quality Improvement
Program was 0.3%. The risk score stratiﬁed patients into low, moderate, and high risk for postdischarge VTE with the
incidence based on the risk score ranging from 0.07% to 2.2%. The risk score had good predictive ability with c-statistic[
0.72 for model development and c-statistic[ 0.71 in the validation dataset. Factors associated with postdischarge VTE
on multivariate analysis included race, increasing age, steroid use, body mass index $30, malignancy, higher American
Society of Anesthesiologists class, increasing operative time, length of postsurgical stay, and major postoperative
complication.
Conclusions: This novel postdischarge VTE prediction score utilizes patient, operative, and early outcome factors to
accurately identify patients at increased risk of a postdischarge thromboembolic event. The development of a patient-
speciﬁc postdischarge VTE risk proﬁle may help address the challenge of determining postdischarge prophylaxis
requirements. (J Vasc Surg 2013;58:1014-20.)Venous thromboembolism (VTE), which includes
deep venous thrombosis (DVT) and pulmonary embolism
(PE), is a signiﬁcant health care issue, with more than 4
million surgical inpatients thought to be at signiﬁcant risk
of VTE yearly in the United States. 1 The magnitude of
the risk has led the Agency for Healthcare Research and
Quality to cite the initiation of VTE prophylaxis as the
most important strategy to improve hospital safety and to
several national initiatives led by the Surgeon General’s
Call to Action to improve utilization of inpatient thrombo-
prophylaxis.2-5 Although these initiatives have mainly
focused on inpatient thromboprophylaxis, it is increasinglythe Surgical Health Outcomes and Research Enterprise, Department
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4recognized that the heightened risk of a VTE secondary to
a surgically induced hypercoagulable state extends well
beyond the inpatient episode. Multiple large prospective
randomized trials have shown a protective effect of post-
discharge thromboprophylaxis.6 Not only is VTE a major
cause of mortality and re-admissions, but a signiﬁcant
proportion of VTE events occur after surgical discharge.6
A number of randomized controlled trials have estab-
lished the efﬁcacy of extended thromboprophylaxis with
low molecular weight heparin beyond the period of hospi-
talization in reducing the risk of VTE in patients deemed to
be at high risk of postdischarge VTE.7-9 Despite guidelines
from the American College of Chest Physicians Guidelines
on Prevention of Venous Thromboembolism (ACCP)
(ninth edition) to consider extended postdischarge throm-
boprophylaxis in patients deemed to be at high risk, there
appears to be a relatively low rate of utilization of post-
discharge thromboprophylaxis in current clinical practice.10
The reasons for the relatively low rate of utilization of
extended prophylaxis are unclear, but may reﬂect a lack of
surgeon awareness of the ongoing risk of a postdischarge
VTE and difﬁculty in identifying those patients who are
at an increased risk of a postdischarge VTE.11 Changes
from the eighth to ninth edition ACCP guidelines include
explicit risk assessment using risk-scoring systems for most
recommendations with the exception of extended duration
thromboprophylaxis. This exception is likely due to lack of
predictive risk scoring systems aimed exclusively at
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were to determine the incidence and risk factors associated
with symptomatic postdischarge VTE and to develop
a broadly applicable risk score utilizing common risk factors
to identify those surgical patients who may beneﬁt from
extended postdischarge thromboprophylaxis.METHODS
The American College of Surgeons National Surgical
Quality Improvement Program (NSQIP) comprises a clin-
ical database with systematic data collection conducted at
hundreds of hospitals throughout the United States.13
Details of the NSQIP sampling strategy, data abstraction,
parameters collected, and recorded outcomes have been
previously reported.13 In brief, the program collects infor-
mation pertaining to patient demographics, preoperative
medical history, clinical ﬁndings, and laboratory investiga-
tions. Postdischarge follow-up data are obtained both
from chart review and standardized patient phone inter-
views by a certiﬁed nurse reviewer with the intention of
capturing complications up to 30 days postoperatively.
The 2005-2009 NSQIP databases were queried for
patients who had undergone nonorthopedic operations.
Procedure types were grouped as follows: (1) general
surgery-intermediate cases (cholecystectomy, any hernia
surgery not involving a concomitant bowel resection), (2)
vascular surgery, (3) urology or gynecology, (4) thoracic
surgery, (5) cardiac surgery, (6) colorectal surgery, (7)
integumentary/maxillofacial/ear/nose/throat, (8) breast
or endocrine, (9) upper gastrointestinal, (10) hepatobili-
ary/pancreas, (11) neurosurgery, and (12) spleen/
lymphatics. Relevant cases were identiﬁed by use of the
current procedural terminology (CPT) codes (Appendix,
online only). Orthopedic cases were excluded from the
dataset. These cases were cross referenced with the primary
discharge diagnosis based on the International Classiﬁca-
tion of Disease-Ninth Revision codes to determine if the
patient had surgery for an underlying malignant or benign
process14 (Appendix, online only).
In the NSQIP system, an episode of DVT is recorded
by the nurse reviewer based on a conﬁrmatory duplex ultra-
sound, venogram, or computed tomography while the
diagnosis of a PE is based on a positive computed tomog-
raphy (spiral or angiogram), pulmonary arteriogram, or
high probability V-Q scan. The end point of interest was
the incidence of VTE events, which included any patient
who had a conﬁrmed DVT or PE in the postdischarge
setting. Postdischarge VTE was calculated as VTE events
where the days to event after operation exceeded days
from operation to discharge. Patients who developed
both a DVT and PE were counted as one event. Patients
who had a VTE prior to discharge were excluded from
the analysis. Cases involving a length of stay from operation
to discharge $15 days and inpatient deaths were also
excluded. This was on the basis that such patients would
have a much shorter length of postdischarge follow-up in
which a VTE end point would be captured. The ﬁnal datasetcontained nonorthopedic cases discharged alive, without an
inpatient VTE, and with a length of stay <15 days.
Preoperative comorbidity variables were grouped by
organ system and analyzed along with other operative
factors such as wound classiﬁcation, American Society of
Anesthesiologists (ASA) score, and duration of operative
procedure (Appendix, online only). Postoperative clinical
complications were grouped by organ system and then
categorized as either major or minor consistent with prior
published methodology.15-17 Only clinical complications
that occurred prior to patient discharge were included in
the analysis. Major complications included organ space
(peritoneal) infections, cardiac events, ventilator depen-
dence (reintubation or failure to wean), pneumonia, return
to the operating room, renal insufﬁciency, cerebrovascular
accident, coma, shock, bleeding, renal failure, and sepsis.
Minor complications included incision site infections
(superﬁcial to the fascia) and urinary tract infections. Post-
operative length of stay was deﬁned as the days from the
operation until discharge and was examined as a categorical
variable (0, 1-3, 4-6, 7-8, and 9-14 days).
The dataset was randomly split with two-thirds allo-
cated for model development (n ¼ 562,791) and one-
third allocated for model validation (n ¼ 281,368). For
model development, the univariate associations between
the independent variables (demographics, history, and
postoperative complications) and 30-day postoperative
outpatient VTE were established using c2 tests. Receiver-
operator characteristic curves were used to establish dichot-
omization points for age (58 years) and operative time
(100 minutes) based on cutoffs best predicting post-
discharge VTE. Variables with a P value of <.2 were
considered for inclusion in the multivariate logistic regres-
sion analysis. The multivariate logistic regression model
containing variables where P < .05 from the development
dataset were then tested using the validation dataset. Inter-
actions between days from operation to discharge (categor-
ical) and signiﬁcant predictors were tested. Variables and
interaction terms that were signiﬁcant (P < .05) for both
the development and the validation datasets were included
in the ﬁnal model. The c-statistic (area under the receiver-
operator characteristic curve) is a measure of predictive
ability. A P value >.05 for the Hosmer and Lemeshow
goodness-of-ﬁt statistic (a measure of precision) means
that there is no statistical difference between the observed
and expected counts for a model with a good c-statistic.
The point scoring system was developed from the
regression coefﬁcients in the ﬁnal multivariate model.18
The total risk score of a patient is the sum of the points
for each risk factor present. The relationship between the
total risk score and VTE was tested against the develop-
ment dataset (observed) and against the validation dataset
(predicted). All analyses were carried out at the University
of Rochester using SAS 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
The incidence of early postdischarge VTE for 2005-
2009 NSQIP was 0.3% (n ¼ 844,159 records). Out of
Table I. Cohort characteristics for those with and
without a postdischarge VTE and univariate analysis
Patient preoperative
characteristics
No
postdischarge
VTE, %
Postdischarge
VTE, %
P
value
No. of patients 841,297 2862
Male sex 41.3 45.6 <.0001
Age $58 44.5 59.3 <.0001
Race <.0001
Caucasian 72.3 78.4
African American 9.5 10.2
Hispanic 7 4.1
Asian/Paciﬁc Islander 2 0.9
Other/unknown 9.1 6.4
Body mass index $30 39.5 44.6 <.0001
Functional status e
dependent
3.9 10.1 <.0001
Current smoker within 1 year 20.5 16.8 <.0001
Alcohol use 2.5 2.4 NS
History of cardiac disease 12.2 15.6 <.0001
History of congestive heart
failure
0.6 1.5 <.0001
Hypertensive medications 43.9 54 <.0001
History of COPD 4.2 6.3 <.0001
Pulmonary comorbidity 0.4 1.1 <.0001
Hepatic insufﬁciency 0.8 2.0 <.0001
Renal insufﬁciency 1.7 2.2 <.05
Neurologic comorbidity 6.5 9.6 <.0001
History of diabetes mellitus 13.7 15.5 <.01
Steroids for chronic
condition
2.7 7.3 <.0001
Bleeding disorders 4.8 9.1 <.0001
Pre-op HCT (<38) 44.8 48.4 <.001
Pre-op sepsis 6.8 10.5 <.0001
ASA class III, IV, and V 41.3 59.8 <.0001
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease; HCT, hematocrit; VTE, venous thromboembolism.
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(71%) had DVT, and 258 (9%) had both a DVT and PE.
The population characteristics and operative factors are
listed in Tables I and II, respectively. On univariate anal-
ysis, patient factors associated with a postdischarge symp-
tomatic VTE included male sex, increasing age, obesity
(BMI $ 30), preoperative comorbidities, preoperative
functional dependence, malignancy, and a history of steroid
usage. A number of operative related factors were associ-
ated with a postdischarge symptomatic VTE. These
included surgery for a malignant condition, prolonged
operative time, a postoperative complication (both major
and minor), and prolonged postoperative length of stay.
Several factors were identiﬁed as independent pre-
dictors of postdischarge VTE after multivariate regres-
sion using the model development dataset (Table III).
The regression model had good predictive ability
(c-statistic ¼ 0.720) and was precise (Hosmer and Leme-
show goodness-of-ﬁt test, P > .23). The factors predicting
postdischarge VTE included age $58 years, operative
time $100 minutes, steroid use, dependent functional
status, obesity, malignancy, nonsmoking status, a major
postoperative inpatient complication, and days from oper-
ation to discharge. There was a signiﬁcant interaction
between the days from operation to discharge and a major
postoperative complication. Multivariate logistic regres-
sion with the type of surgical procedure as a variable
had poor precision (Hosmer and Lemeshow test, P <
.05) and, therefore, the type of procedure was not con-
sidered in the ﬁnal model.
The model development dataset was then used to
generate a point scoring system for each signiﬁcant predic-
tive factor (Table IV). Point values ranged from a minimum
of negative 1 point for a current smoker to 4 points for
steroid use. To calculate a total postdischarge VTE risk
score, points are tallied for preadmission steroid use, age,
preoperative functional status, operative time, obesity
(BMI $30), malignancy, and smoking status. Additional
points are then added for days from operation to discharge
depending on whether or not a major inpatient complica-
tion occurred.
Logistic regression was used to evaluate the ability of
the total risk score to predict postdischarge VTE within
the model development dataset (Table V). Total point
scores in the model development set ranged from e1 point
to >23 points. The upper 0.1% of the population had point
scores of 19 or greater. Because of the small number of
cases in the upper range, they were combined with 18
points to create the category $18 points representing
a cohort with >2% predicted probability of VTE. The pre-
dicted probability of VTE based on the point scores ranged
from 0.07% for e1 point to 2.17% for 18 or more points.
The postdischarge VTE score was then validated against
the remaining one-third of the dataset using logistic regres-
sion. The agreement between the predicted probability of
VTE from the development dataset and the observed prob-
ability of postdischarge VTE from the validation dataset is
shown in Fig 1. This multivariate regression model alsoshowed good predictive ability for the validation data
(c-statistic ¼ 0.713) and was precise (Hosmer and Leme-
show goodness-of-ﬁt test, P > .75). The probability of
a postdischarge VTE was greater than 1% for point scores
of 14 or greater. Predicted postdischarge VTE from the
model development dataset were then categorized as low,
medium, or high risk. High risk was deﬁned as a predicted
postdischarge VTE risk of $1%. The high risk group
comprising patients with a total score of $14 had
a 1.35% risk of postdischarge VTE (5.3% of total study
population) (Fig 2). A total score from 9 to 13 deﬁned
the medium risk category (18.6% of the population) with
a corresponding risk of 0.68%. The low risk group had
a total risk score of <8 and an estimated 0.19% risk
(76.1% of the population).
DISCUSSION
A broadly applicable point scoring system comprising
six patient characteristics, one operative factor, and two
early postoperative end points was developed and validated
for the risk stratiﬁcation of postdischarge VTE. Together
these factors can predict a high risk subgroup where the
comprising upper 5% of the population have higher
Table II. Multivariate factors associated with
postdischarge VTE
Patient operative
characteristics
No
postdischarge
VTE, %
Postdischarge
VTE, %
P
value
Operative indication
Malignant condition 15.5 24.1 <.0001
Inﬂammatory bowel
disease
0.9 2.4 <.0001
Blood transfusion 4 10.8 <.0001
Wound class III or IV 13.6 15.7 <.01
Total operation time
$100 minutes
40.5 62.4 <.0001
Predischarge major
complication
5.3 17 <.0001
Predischarge minor
complication
1.3 3.1 <.0001
Surgical category <.0001
Integumentary/
maxillofacial/ENT
2.4 2.0
Thoracic 1.0 1.8
Upper GI 9.1 10.2
Urology/gynecology 4.8 4.9
Vascular 11.5 16
Breast/endocrine 16.2 5.6
Cardiac 0.7 2.3
Colorectal 16.7 29.4
General-intermediate 32.9 16.5
Hepatobiliary/
pancreas
3.3 7.3
Neurosurgery 0.3 1.4
Spleen/lymphatic/
other
1.1 2.6
Days from OR to
discharge
<.0001
0 30.4 12.2
1-3 43.4 31.9
4-6 14.8 26.1
7-8 5.8 14.6
9-14 5.6 15.2
ENT, Ear, nose, and throat; GI, gastrointestinal; OR, operating room; VTE,
venous thromboembolism.
Table III. Risk score multivariate model for
postdischarge VTE
OR (95% CI) P value
Age, $58 years 1.38 (1.25-1.52) <.0001
Operative time, $100 minutes 1.48 (1.33-1.65) <.0001
Steroid use 2.08 (1.74-2.48) <.0001
Functional status, dependent 1.39 (1.13-1.7) <.0005
BMI $30 1.39 (1.27-1.53) <.0001
Smoker, yes 0.84 (0.74-0.95) <.01
Malignancy 1.29 (1.15-1.44) <.0001
Beta
Postoperative major complication,
1 vs 0
0.879 <.005
Days from operation to discharge <.0001
0 Reference
1-3 0.3371
4-6 1.1092
7-8 1.3766
9-14 1.479
LOS* major complication <.0001
0 Reference
1-3 0.5705
4-6 0.763
7-8 0.3384
9-14 0.6832
BMI, Body mass index; CI, conﬁdence interval; LOS, length of stay; OR,
odds ratio; VTE, venous thromboembolism.
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for scores 14 to $18).
Obesity, dependent functional status, malignancy, and
increasing patient age are all well-recognized risk factors for
VTE.12,19-21 The relationship between steroid use and
postdischarge VTE is an intriguing one because the indica-
tions for steroid use cannot always be identiﬁed from the
NSQIP database. Steroid use could be a surrogate marker
for an underlying autoimmune or inﬂammatory condition
which predisposes individuals to thrombosis.20,22 The
putative association between smoking and postdischarge
VTE may represent a type I error since prior reports have
failed to show a relationship between smoking and post-
operative VTE.23,24
An operative time of greater than or equal to 100
minutes, regardless of the operative indication was inde-
pendently associated with an increased risk of a post-
discharge VTE. Rogers et al have previously reported
that a high relative value unit (RVU) was associated withthe subsequent 30-day VTE rate, whereas a correlation
between RVUs and operative time has also been
shown.23,25 RVUs are not readily available at the time of
discharge planning; however, operative time can be easily
be obtained from the operating room records. Therefore,
it is postulated that operative time would serve as a surro-
gate marker for case complexity. The association between
prolonged operative time and postdischarge VTE supports
the use of operative time as a simple measure of surgical
complexity. Postoperative major in-hospital complications
included both organ impairment and systemic sepsis.
Inﬂammation may inhibit ﬁbrinolysis and promote throm-
bosis at both a local and systemic level.20,26 This increased
risk is compounded by the relative immobility of such
patients in the postdischarge residential setting. Lastly,
the probability of a postdischarge VTE was increased
with longer postoperative stays consistent with the associa-
tion between all VTE and total length of stay.19,25
There are two approaches to determining a patient’s
need for extended thromboprophylaxis: group risk assess-
ment and the use of risk assessment models to estimate an
individual patient’s risk. The group risk assessment model
is used by the ACCP (ninth edition).10 However the guide-
lines are relatively vague with consideration for extended
prophylaxis suggested for “some of those who have under-
gone major cancer surgery or have previously had VTE.”10
The guideline for extended duration thromboprophylaxis
is in stark contrast to inpatient thromboprophylaxis guide-
lines where individual risk assessment using speciﬁc risk
scores is recommended. This broad and vague guideline fails
Table V. Predicted postdischarge VTE risk based on the
total risk score
Total risk score
Predicted risk of
postdischarge VTE, % No. of patients
1 0.07 13,403
0 0.08 42,626
1 0.07 24,532
2 0.14 84,793
3 0.15 26,890
4 0.17 80,887
5 0.2 29,214
6 0.29 61,978
7 0.35 20,839
8 0.34 32,047
9 0.5 17,732
10 0.59 30,269
11 0.78 16,455
12 0.72 23,813
13 0.93 13,636
14 1.09 12,384
15 1.49 6,424
16 1.27 5,205
17 1.7 2,057
$18 2.17 2,839
BMI, Body mass index; VTE, venous thromboembolism.
14,979 records are missing BMI data.
Table IV. Point scores for postdischarge VTE
Independent variables
Points
to add
Points for
individual
patient
Steroid use 4
Age $58 years 2
Operative time
$ 100 minutes
2
Dependent
functional status
2
BMI $30 2
Current smoker e1
Days from operation
to discharge
Major
complication
0-1 Yes 5
No 0
1-3 Yes 10
No 2
4-6 Yes 12
No 6
7-8 Yes 11
No 8
9-14 Yes 10
No 8
Total postdischarge risk score (sum of ﬁnal column)
BMI, Body mass index; VTE, venous thromboembolism.
Mark relevant points in right-hand column; ﬁnal cell equals sum of the
right-hand column.
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Fig 1. The predicted probability of a postdischarge venous
thromboembolism (VTE) from the development dataset (circles)
shows good agreement with the observed probability from vali-
dation data set (squares) c-statistic ¼ 0.72 in the development
model, and c-statistic ¼ 0.71 in the validation dataset.
0.0%
0.2%
0.4%
0.6%
0.8%
1.0%
1.2%
1.4%
1.6%
Pr
ed
ic
te
d 
po
st
-d
isc
ha
rg
e 
V
TE
Low 
-1 to 8
76.1%
Medium
9 to 13
18.6%
High 
5.3% 
Risk Level
Point scores
% of population
Fig 2. The predicted postdischarge venous thromboembolism
(VTE) probability was subdivided into three categories. The low
risk group had a predicted probability of 0.19% whereas the
medium risk group had a predicted probability of 0.68% and the
high risk group had a predicted probability of 1.35%. Data are
probability þ standard error.
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discharge VTE risk score. First, the guideline seems to apply
to all abdominal oncologic resections. Indeed the NationalComprehensive Cancer Network thromboprophylaxis
guidelines suggest all patients undergoing major abdominal
and pelvic oncologic resections should receive thrombopro-
phylaxis. Surgeons may be reluctant to broadly apply this
hard and fast rule. Our risk score allows selective use of
extended thromboprophylaxis as not all malignant resec-
tions will meet high risk criteria. Similarly, the guidelines
may fall short of recommending thromboprophylaxis in
patients who are not undergoing oncologic resection yet
JOURNAL OF VASCULAR SURGERY
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extended duration thromboprophylaxis.
Previous studies have demonstrated the feasibility of
a scoring system to risk stratify patient subgroups and to
predict the probability of VTE over the total 30-day post-
operative period, incorporating both the inpatient and
postdischarge period.19,23 Bahl et al assigned a VTE risk
category (low, medium, high, and highest) to 8216
patients based on the Caprini risk assessment model.19
The overall incidence of VTE within 30 days was 1.44%,
though no breakdown on the proportion of in-patient to
postdischarge events is provided. There was a signiﬁcant
difference in VTE incidence between the high (0.97%)
and the highest (1.94%) level risk categories. Although
a probability of 1% or greater may be a suitable cutoff for
higher risk, a drawback to this categorization scheme in
determining postdischarge prophylaxis requirements is
that a large majority of their cohort, 88.6%, was in the
high risk or highest risk category. Unlike their 30-day post-
operative risk stratiﬁcation system, our postdischarge VTE
risk score focuses on identifying the subset of people in
whom extended postdischarge prophylaxis should be
strongly considered. The postdischarge VTE score was
categorized to identify patients with an elevated risk of
VTE, which was taken to be a predicted risk of $1%.
This model would allow the identiﬁcation of the small
cohort of patients (5.3% of population) at a heightened
risk of a postdischarge VTE. Furthermore, the Caprini
risk score incorporates 40 factors, some of which may be
difﬁcult to obtain, such as family history of thrombosis
and hypercoagulation proﬁles not routinely performed,
such as elevated serum homocysteine or lupus anticoagu-
lant.19,27 Our model was designed to be simple and easy
to use clinically with only eight total factors.
The overall incidence of postdischarge VTE was 0.3%,
which is signiﬁcantly less than previous reports.28 There
may be various sources of discrepancy between this study
and the Million Women Study, and the biggest distinction
is the time period. NSQIP only evaluates events up to 30
days postoperatively, whereas the Million Women Study
followed patients for 12 weeks. Another major difference
between these two studies is that the Million Women Study
was performed in England, where Hospital Episodes Statis-
tics data from the National Health Service (NHS) were used
to track patients. Patients tracked in NSQIP are much less
likely to have events captured if they present at another
hospital, whereas in the NHS these outside events are
much more likely to be captured. The relatively lower post-
discharge VTE rate in the current study does not have
a major impact on the overall risk score. Missing post-
discharge VTE events would bias effect estimates for each
covariate toward the null; however, relative weighting
remains the same, and thus the risk score would not likely
be altered.
It is important to acknowledge certain limitations of the
NSQIP dataset. For example, NSQIP does not include data
on most home medications that may impact on VTE or on
inpatient thromboprophylaxis. It is also conceivable thatsome patients were discharged on extended thrombopro-
phylaxis, though this information is not available via
NSQIP. Studies to date suggest the use of extended throm-
boprophylaxis in nonorthopedic surgery remains relatively
low with a utilization rate of only 30% in patients post onco-
logical surgery.11,29 Another weakness is that the follow-up
period of 30 days provided by NSQIP is relatively short as
the Million Women Study has shown that duration of
elevated postsurgical VTE risk extends out to 12 weeks.28
In addition, this current study population is not randomly
selected and reﬂects the case mix of the hospitals who utilize
the NSQIP system to audit their activity. Another limitation
of this study is potential misclassiﬁcation of postdischarge
events because of a potential lag time for symptom develop-
ment. Althoughdifﬁcult to ascertain the extent of this poten-
tial misclassiﬁcation, it may suggest patients at high risk
should be screened with ultrasound prior to discharge or
extended duration thromboprophylaxis initiation. Notwith-
standing these limitations, the strength of theNSQIPdataset
is that it offers the opportunity to identify risk factors associ-
ated with early postdischarge VTE in a large cohort of
patients where both preoperative and postoperative factors
are collected in a consistent and validated manner.
The decision to initiate postdischarge prophylaxis is
a challenging one where the risk of a postdischarge throm-
boembolic event must be weighed against the potential
increased risk of bleeding on any form of pharmacologic
prophylaxis. As noted in the ACCP guidelines, the atten-
dant costs in terms of patient inconvenience and ﬁnancial
costs must also be considered.10 Given a risk reduction of
50%, the number needed to treat would be 90. However,
given that the overall incidence in this study was 15% of
that in the Million Women Study if one scaled this for
the high risk group, the number needed to treat would
be 14. The postdischarge VTE risk score provides a simpli-
ﬁed scoring system that could be a readily incorporated
into a guide for discharge thromboprophylaxis planning.
The risk score is easy to use, incorporating clinical features
that are readily available and broadly applicable across
surgical specialties. We would propose that any patient
with a risk score of 14 or greater should be considered
for postdischarge prophylaxis as this cohort has a predicted
postdischarge VTE risk of 1.09% to at least 2.17%.
However, a cost-effectiveness analysis ought to be per-
formed to conﬁrm what score should be used as a cutoff
for prophylaxis implementation. A blanket policy of imple-
menting postdischarge prophylaxis in this cohort may not
be appropriate for all patients and across surgical specialties.
Nevertheless, the use of a patient-speciﬁc VTE risk proﬁle
provides a more rational basis for determining the need
for postdischarge prophylaxis that may guide clinicians in
identifying patients at increased risk for postdischarge VTE.AUTHOR CONTRIBUTIONS
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Methods
CPT codes
Orthopedic cases (these CPT codes were excluded):
20000-21009, 21800-21898, 22010-22898, 23020-29999,
62360-75949
Nonorthopedic cases (included):
Skin/Maxillo-Facial/Ear, Nose, and Throat: 10120-
19019, 21010-21799, 21930, 21935, 40500-43019
Breast/Endocrine: 19020-19999, 60200-61149
Colorectal: 22900-22999, 44000-44899, 45000-46999,
49000-49499
Thoracic: 31610-33019, 39000-40499
Cardiac: 33020-33999
Vascular: 34000-38099
Upper GI: 43020-43999
Hepatobiliary/Pancreas: 47000-47559, 47600-48999
General Surgery: 44900-44999, 47560-47599, 49500-
50009
Urology/Gynecology: 50010-59999
Neurosurgery: 61150-62359
International Classiﬁcation of Disease-Ninth Revision codes
used to identifymalignancy: 140-208, 209-209.3,V10.00-
V10.07, V10.09, V10.11, V10.12, V10.20-V10.22,V10.29,V10.3,V10.40-V10.44,V10.46-V10.49,V10.50-
V10.53,V10.59,V10.60-V10.63,V10.69,V10.71,V10.72,
V10.79,V10.81-V10.89,V10.9,V10.91,V58.0,V58.11,
V71.1.
Categorization of comorbid variables:
Race was categorized as White, Black, Hispanic, Asian, or
Paciﬁc Islander, and other or unknown. Diabetes was
dichotomized as yes or no. A history of liver disease
included ascites or esophageal varices. A history of cardiac
disease was deﬁned as a history of myocardial infarction,
previous percutaneous intervention or stenting, a history
of angina, and a history of peripheral vascular disease or
rest pain. A history of renal disease included renal failure
or dialysis. Transfusion was dichotomized as any intra-
operative or preoperative transfusion. Functional status
was dichotomized as independent or not at the time of
surgery. ASA class was dichotomized as I-II and III-V.
Within NSQIP, preoperative steroid use is deﬁned as
regular administration of corticosteroid medication in the
30 days before surgery. A history of “bleeding disorder”
identiﬁes an individual with a history of an endogenous
blood clotting element deﬁciency (hemophilia, thrombo-
cytopenia) or who is on any nondiscontinued medication
that inhibits blood clotting (anticoagulants or antiplatelet
agents except aspirin).
